Biofrontera AG signs non-binding term sheet for licensing agreement for Ameluz® in Poland with medac GmbH Sp. z o.o.
13 mars 2020 08h00 HE
|
Biofrontera AG
Leverkusen, Germany, March 13, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) today signed a non-binding term sheet for an exclusive license agreement with...
Biofrontera AG extends subscription period for mandatory convertible bonds
12 mars 2020 13h53 HE
|
Biofrontera AG
Leverkusen, Germany, March 12, 2020 (GLOBE NEWSWIRE) -- On February 26, 2020, Management Board resolved to issue up to 1,600,000 of the 0.5% qualified subordinated mandatory convertible bonds...
European Commission approves use of Ameluz® for the treatment of actinic keratosis on extremities and trunk/neck
10 mars 2020 11h00 HE
|
Biofrontera AG
Leverkusen, Germany, March 10, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced that...
Biofrontera entered into binding term sheet with Maruho Co., Ltd.
03 mars 2020 06h00 HE
|
Biofrontera AG
Leverkusen, Germany, March 03, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ ticker symbol: BFRA, ISIN: DE0006046113), an international biopharmaceutical company, announces that it has entered...
Biofrontera AG resolves to issue qualified subordinated mandatory convertible bonds
26 févr. 2020 08h25 HE
|
Biofrontera AG
Leverkusen, Germany, Feb. 26, 2020 (GLOBE NEWSWIRE) -- The Executive Board of Biofrontera AG (NASDAQ ticker symbol: BFRA, ISIN: DE0006046113), today resolved, with the approval of the Supervisory...
Biofrontera provides clinical development updates
19 févr. 2020 05h45 HE
|
Biofrontera AG
Leverkusen, Germany, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today provides an...
European Medicines Agency recommends indication expansion of Ameluz® for treatment of actinic keratoses on the extremities and trunk/neck
03 févr. 2020 05h45 HE
|
Biofrontera AG
Leverkusen, Germany, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announced today that...
Organizational restructuring of Biofrontera and resignation of Chief Commercial Officer Christoph Dünwald
31 janv. 2020 11h38 HE
|
Biofrontera AG
Leverkusen, Germany, Jan. 31, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announced today that...
Biofrontera announces 1-year follow-up results for its phase III study of photodynamic therapy for actinic keratosis on the extremities and trunk/neck
14 janv. 2020 00h30 HE
|
Biofrontera AG
Leverkusen, Germany, Jan. 14, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced...
Biofrontera announces preliminary sales figures for the full year 2019, record sales in the 4th quarter
10 janv. 2020 05h00 HE
|
Biofrontera AG
Leverkusen, Germany, Jan. 10, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced its...